Data as of Apr 15
| -0.04 / -0.16%|
TESARO, Inc. is an oncology-focused biopharmaceutical company. It is dedicated to improving the lives of cancer patients. The company's product portfolio currently consists of three oncology-related product candidates: Rolapitant, a potent and long-acting neurokinin-1, receptor antagonist currently in phase 3 clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, formerly known as MK-4827, is an orally active and potent poly polymerase, inhibitor that has undergone a phase 1 clinical trial in cancer patients as a monotherapy and is currently under evaluation by Merck & Co., Inc., for use in combination with temozolomide for the treatment of solid tumors; and TSR-011, an orally available anaplastic lymphoma kinase, inhibitor currently in preclinical development. These product candidates intend to make them available to cancer patients in North America, Europe and China through its commercialization efforts and to establish a network of licensees and distributors in other geographic areas. It plans to test TSR-011 in clinical trials as a treatment for non-small cell lung cancer, and potentially other cancer indications. TESARO was founded by Leon Moulder, Jr., Mary Lynne Hedley and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA.
|Leon O. Moulder||Chief Executive Officer & Director|
|Mary Lynne Hedley||President, Director & Chief Scientific Officer|
|Edward C. English||Chief Financial Officer, VP & Controller|
|Robert E. Martell||Chief Medical Officer|
|Jennifer Davis||Senior Director-Investor Relations|